NCT05759923: First-in-human Phase I Study to Evaluate Safety, Tolerability and Antineoplastic Activity of OATD-02 in Patients With Selected Advanced and/or Metastatic Solid Tumours

Sponsor: Molecure S.A.. Phase: PHASE1. Conditions: Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Colorectal Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Renal Cell Carcinoma, Metastatic Ovarian Carcinoma